AMSTERDAM, May 22, 2017 /PRNewswire/ -- Recently
published advancements in pulmonary research suggest that the
combination of non-invasive ventilation (NIV) and home oxygen
therapy (HOT) can significantly prolong time to readmission or
death for patients with chronic obstructive pulmonary disease
(COPD) following a life-threatening respiratory event or
exacerbation. The five-year, multi-center study resulted in
prolonged median time to readmission or death by nearly three
months, and improved patient health-related quality of life in the
first six weeks.
"Patients with severe COPD and persistent hypercapnia have
historically had limited therapy options available to them and
outcomes have generally been poor," said Dr. Nicholas Hart, Professor and Clinical Director
of Lane Fox Respiratory Service, St Thomas' Hospital in
London. "The trial suggests that
combining home oxygen and home non-invasive ventilation therapy can
reduce hospital readmissions while maintaining patients' quality of
life, which will drastically change the way we approach COPD
treatment worldwide. We are looking forward to hopefully decreasing
the mortality and readmission rates that result from severe COPD
with further research."
The randomized clinical trial of 116 patients in the
United Kingdom was co-sponsored by
Royal Philips (NYSE: PHG; AEX: PHIA) and carried out by respiratory
experts at St Thomas' Hospital in London. The results showed that the addition
of home NIV prolonged the median time to readmission or death from
1.4 months to 4.3 months.
"This study shows that home non-invasive ventilation is a
potent, therapeutic tool that clinicians can use to help keep
patients with advanced COPD out of the hospital. We hope that this
will, in turn, allow them to lead healthier and more active
lives at home," said Dr. Teofilo Lee-Chiong
Jr., Chief Medical Liaison at Philips. "These findings add
considerably to our knowledge of this highly prevalent and
debilitating respiratory disorder, and are expected to greatly
influence how clinicians care for patients with COPD on long-term
oxygen therapy."
Preliminary results from this trial were announced in
September 2016 at the European
Respiratory Society's International Congress in London, U.K. The final paper, entitled
Effect of home non-invasive ventilation with oxygen therapy vs.
oxygen therapy alone on hospital readmission or death after an
acute COPD exacerbation: A randomized clinical trial, was
published in the Journal of the American Medical Association after
being presented at the American Thoracic Society International
Conference (Washington, D.C.,
U.S., May 19 – 24).
In April 2017, another
Philips-sponsored study demonstrated significant cost savings for
payers and hospitals from reduced COPD readmission rates resulting
from a multifaceted care program that included the use of AVAPS-AE,
a proprietary mode of non-invasive ventilation in the Trilogy
device. Philips' sponsorship of these studies is the latest in the
company's continued commitment to pioneering the development of
home NIV technologies and ultimately helping COPD patients breathe
easier.
Philips works every day to support COPD patients and help them
improve their quality of life by offering a range of solutions,
including advanced NIV therapies such as the DreamStation BiPAP
AVAPS and S/T, BiPAP A40 (available outside the United States) and Trilogy. Today, Philips
is enabling more efficient patient management with the expansion of
its connected Trilogy and Care Orchestrator, now commercially
available in North America. For
additional information on Philips' solutions for sleep and
respiratory care, follow @PhilipsResp or visit
www.respironics.com.
For further information, please contact:
Meredith Amoroso
Philips Sleep and Respiratory Care
Mobile: +1 724-584-8991
E-mail: meredith.amoroso@philips.com
Elena Calamo Specchia
Philips Group Press Office
Mobile: +31 6 25004735
E-mail: elena.calamo.specchia@philips.com
About Royal
Philips
Royal Philips
(NYSE: PHG, AEX: PHIA) is a leading health technology company
focused on improving people's health and enabling better outcomes
across the health continuum from healthy living and prevention, to
diagnosis, treatment and home care. Philips leverages advanced
technology and deep clinical and consumer insights to deliver
integrated solutions. Headquartered in the Netherlands, the company is a leader in
diagnostic imaging, image-guided therapy, patient monitoring and
health informatics, as well as in consumer health and home care.
Philips' health technology portfolio generated 2016 sales of
EUR 17.4 billion and employs
approximately 71,000 employees with sales and services in more than
100 countries. News about Philips can be found at
www.philips.com/newscenter.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/philips-sponsored-clinical-study-demonstrates-significant-breakthrough-for-copd-treatment-300461153.html
SOURCE Royal Philips